Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial
Ronald P. DeMatteo, Karla V. Ballman, Cristina R. Antonescu, Christopher Corless, Violetta Kolesnikova, Margaret Von Mehren, Martin D. McCarter, Jeffrey Norton, Robert G. Maki, Peter W.T. Pisters, George D. Demetri, Murray F. Brennan, Kouros Owzar
Research output: Contribution to journal › Article › peer-review
126Scopus
citations
Fingerprint
Dive into the research topics of 'Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial'. Together they form a unique fingerprint.